234 related articles for article (PubMed ID: 34583214)
1. ProspeCtive study to evaluate efficacy, safety and tOlerability of dietary supplemeNT of Curcumin (BCM95) in subjects with Active relapsing MultIple Sclerosis treated with subcutaNeous Interferon beta 1a 44 mcg TIW (CONTAIN): A randomized, controlled trial.
Petracca M; Quarantelli M; Moccia M; Vacca G; Satelliti B; D'Ambrosio G; Carotenuto A; Ragucci M; Assogna F; Capacchione A; Lanzillo R; Morra VB
Mult Scler Relat Disord; 2021 Nov; 56():103274. PubMed ID: 34583214
[TBL] [Abstract][Full Text] [Related]
2. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
[TBL] [Abstract][Full Text] [Related]
3. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
[TBL] [Abstract][Full Text] [Related]
4. Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study.
Traboulsee A; Al-Sabbagh A; Bennett R; Chang P; Li DK; ;
BMC Neurol; 2008 Apr; 8():11. PubMed ID: 18426595
[TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.
Zhang J; Shi S; Zhang Y; Luo J; Xiao Y; Meng L; Yang X
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD010968. PubMed ID: 29178444
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study.
Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
BMC Neurol; 2018 May; 18(1):68. PubMed ID: 29751787
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
Sanford M; Lyseng-Williamson KA
Drugs; 2011 Oct; 71(14):1865-91. PubMed ID: 21942977
[TBL] [Abstract][Full Text] [Related]
8. Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS.
Freedman MS; Brod S; Singer BA; Cohen BA; Hayward B; Dangond F; Coyle PK
J Neurol; 2020 Jan; 267(1):64-75. PubMed ID: 31559532
[TBL] [Abstract][Full Text] [Related]
9. Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a.
Vrenken H; Battaglini M; de Vos ML; Nagtegaal GJ; Teixeira BCA; Seitzinger A; Jack D; Sormani MP; Uitdehaag BMJ; Versteeg A; Comi G; Kappos L; De Stefano N; Barkhof F
J Neurol; 2023 Apr; 270(4):2271-2282. PubMed ID: 36723685
[TBL] [Abstract][Full Text] [Related]
10. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.
De Stefano N; Sormani MP; Stubinski B; Blevins G; Drulovic JS; Issard D; Shotekov P; Gasperini C
J Neurol Sci; 2012 Jan; 312(1-2):97-101. PubMed ID: 21880336
[TBL] [Abstract][Full Text] [Related]
12. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
Barkhof F; Kappos L; Wolinsky JS; Li DKB; Bar-Or A; Hartung HP; Belachew S; Han J; Julian L; Sauter A; Napieralski J; Koendgen H; Hauser SL
Neurology; 2019 Nov; 93(19):e1778-e1786. PubMed ID: 31484710
[TBL] [Abstract][Full Text] [Related]
13. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.
Cohen BA; Rivera VM
Curr Med Res Opin; 2010 Apr; 26(4):827-38. PubMed ID: 20121658
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes.
De Stefano N; Comi G; Kappos L; Freedman MS; Polman CH; Uitdehaag BM; Hennessy B; Casset-Semanaz F; Lehr L; Stubinski B; Jack DL; Barkhof F
J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):647-53. PubMed ID: 24292999
[TBL] [Abstract][Full Text] [Related]
15. Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study.
Freedman MS; Francis GS; Sanders EA; Rice GP; O'Connor P; Comi G; Duquette P; Metz L; Murray TJ; Bouchard JP; Abramsky O; Pelletier J; O'Brien F; ;
Mult Scler; 2005 Feb; 11(1):41-5. PubMed ID: 15732265
[TBL] [Abstract][Full Text] [Related]
16. Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study.
Pena Rossi C; Hanauer SB; Tomasevic R; Hunter JO; Shafran I; Graffner H
BMC Gastroenterol; 2009 Mar; 9():22. PubMed ID: 19302707
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial].
Boyko AN; Boyko OV; Bakhtiyarova KZ; Gusev EI; Dudin VA; Zaslavsky LG; Malkova NA; Parshina YV; Poverennova IY; Siverceva SA; Totolyan NA; Shchur SG; Fedulov AS; Khabirov FA; Bolsun DD; Zinkina-Orikhan AV; Linkova YN; Chernovskaya TV
Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(1):62-71. PubMed ID: 35175704
[TBL] [Abstract][Full Text] [Related]
18. Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.
Arnold DL; Fisher E; Brinar VV; Cohen JA; Coles AJ; Giovannoni G; Hartung HP; Havrdova E; Selmaj KW; Stojanovic M; Weiner HL; Lake SL; Margolin DH; Thomas DR; Panzara MA; Compston DA;
Neurology; 2016 Oct; 87(14):1464-1472. PubMed ID: 27590291
[TBL] [Abstract][Full Text] [Related]
19. [A comparative placebo-controlled clinical study on the efficacy and safety of interferon beta-1a for subcutaneous injections in patients with remitting multiple sclerosis: results of the first year of observations].
Boyko AN; Bosenko LP; Vasilovskiy VV; Volkova LI; Zakharova MN; Kotov SV; Lekomtseva EV; Negrich TI; Parshina EV; Patrusheva OP; Prokopenko SV; Sazonov DV; Timchenko PV; Trinitatskiy YV; Khabirov FA; Khavunka MY; Chichanovskaya LV; Sherman MA; Lin'kova YN; Zinkina-Orikhan AV; Tursunova KB
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(2. Vyp. 2):107-113. PubMed ID: 28617368
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
Cohen JA; Comi G; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Huang V; Kappos L;
Lancet Neurol; 2019 Nov; 18(11):1021-1033. PubMed ID: 31492652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
